Opinion
2015-10-9
Brown Chiari, LLP, Lancaster (Michael Scinta of Counsel), for Plaintiffs–Appellants. Gibson, McAskill & Crosby, LLP, Buffalo (Sally J. Broad of Counsel), for Defendants–Respondents.
Brown Chiari, LLP, Lancaster (Michael Scinta of Counsel), for Plaintiffs–Appellants. Gibson, McAskill & Crosby, LLP, Buffalo (Sally J. Broad of Counsel), for Defendants–Respondents.
PRESENT: SCUDDER, P.J., SMITH, CARNI, LINDLEY, AND DeJOSEPH, JJ.
MEMORANDUM:
Plaintiffs, a group of over 1,900 patients who received insulin injections while at Olean General Hospital (defendant) between November 2009 and January 2013, appeal from an order denying their motion for class certification pursuant to CPLR 902. We conclude that Supreme Court properly denied the motion. This action is based on a letter received by plaintiffs from defendant in January 2013 informing them that, during the period in which they were hospitalized, insulin pens may have been shared by more than one patient, although defendant had not identified any particular patient who had received an insulin injection from an insulin pen used on another patient. The letter also offered free and confidential testing for hepatitis B, hepatitis C and HIV. The complaint, in its present form, asserts causes of action for negligence, malpractice, and loss of consortium.
“[A] class action may be maintained in New York only after the five prerequisites set forth in CPLR 901(a) have been met, i.e., the class is so numerous that joinder of all members is impracticable, common questions of law or fact predominate over questions affecting only individual members, the claims or defenses of the representative parties are typical of the class as a whole, the representative parties will fairly and adequately protect the interests of the class, and a class action is superior to other available methods for the fair and efficient adjudication of the controversy” (Rife v. Barnes Firm, P.C., 48 A.D.3d 1228, 1229, 852 N.Y.S.2d 551, lv. dismissed in part and denied in part10 N.Y.3d 910, 861 N.Y.S.2d 270, 891 N.E.2d 305). The class representative “bears the burden of establishing compliance with the requirements of both CPLR 901 and 902” (Ackerman v. Price Waterhouse, 252 A.D.2d 179, 191, 683 N.Y.S.2d 179).
Where, as here, no plaintiff has tested positive for the blood-borne disease to which he or she allegedly was exposed as a result of defendant's negligence, a prerequisite to recovery is proof of actual exposure to the blood-borne disease ( see e.g. Ornstein v. New York City Health & Hosps. Corp., 10 N.Y.3d 1, 6, 852 N.Y.S.2d 1, 881 N.E.2d 1187; Siegrist v. State of New York, 55 A.D.3d 717, 718, 868 N.Y.S.2d 670). The issue of actual exposure will require individualized determinations with respect to each plaintiff. Further, even if members of the proposed class could establish such actual exposure, “the extent of the damages resulting therefrom [is a] question [ ] requiring individual investigation and separate proof as to each individual claim” (Komonczi v. Fields, 232 A.D.2d 374, 375, 648 N.Y.S.2d 151). Thus, we conclude that, “even if there are common issues in this case, those issues do not predominate” (Geiger v. American Tobacco Co., 277 A.D.2d 420, 421, 716 N.Y.S.2d 108, lv. dismissed96 N.Y.2d 754, 725 N.Y.S.2d 279, 748 N.E.2d 1075), and “[t]he predominance of individualized factual questions ... renders this case unsuitable for class treatment” (Dimich v. Med–Pro, Inc., 34 A.D.3d 329, 330, 826 N.Y.S.2d 3, lv. dismissed in part and denied in part8 N.Y.3d 904, 834 N.Y.S.2d 76, 865 N.E.2d 1242; seeCPLR 901[a][2] ).
It is hereby ORDERED that the order so appealed from is unanimously affirmed without costs.